3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
13
Breast Neoplasms
11
Carcinoma, Transitional Cell
6
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Neoplasm Metastasis
4
Lung Neoplasms
3
Small Cell Lung Carcinoma
2
Urothelial Bladder Carcinoma
1
Salivary Gland Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Localized Muscle Invasive Bladder Urothelial Carcinoma
1
Liver Failure
1
HRD Cancer
1
Glioblastoma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Carcinoma, Small Cell
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
pembrolizumab
64
Cisplatin
44
Cetuximab
26
Carboplatin
25
Paclitaxel
19
Magnetic Resonance Spectroscopy
19
Radiotherapy, Intensity-Modulated
17
Nivolumab
17
Radiotherapy
16
Specimen Handling
15
Docetaxel
14
Platinum
13
1,2-diaminocyclohexaneplatinum II citrate
12
Taxes
8
Fluorouracil
8
Biopsy
8
atezolizumab
6
Radiation
6
(225)Ac-DOTA-c(RGDyK)
6
dostarlimab
5
cemiplimab
5
Ipilimumab
5
Immunoglobulin G
5
Cyclophosphamide
5
Surgical Procedures, Operative
4
Standard of Care
4
Immune Checkpoint Inhibitors
4
Disulfides
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
sacituzumab govitecan
×
90 days
×
Clear all
No trials found.